Campath Leukemia Trial Vs. Alkylating Agents Could Confirm Approval - Cmte
Executive Summary
Comparing Millennium/Ilex' Campath to alkylating agents that are second-line to Berlex' Fludara in the treatment of chronic lymphocytic leukemia could be an option for a confirmatory trial under accelerated approval, FDA's Oncologic Drugs Advisory Committee suggested Dec. 14.